Guenter Janhofer - 23 Oct 2023 Form 3 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Chief Scientific Officer
Signature
/s/ Brendan Hannah, Attorney-in-Fact for Guenter Janhofer, M.D., Ph.D.
Issuer symbol
QNCX
Transactions as of
23 Oct 2023
Net transactions value
$0
Form type
3
Filing time
24 Oct 2023, 19:34:27 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding QNCX Common Stock 15,008 23 Oct 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.